Evidence-based solutions that challenge the status quo

Nonalcoholic steatohepatitis (NASH) represents a public health issue around the world, with no current treatment and heavy consequences on healthcare systems.  The complexities of diagnosing patients, the lack of awareness around the disease, and the reality of moving patients toward treatments that don’t yet exist – it is a perfect storm. And it is clouding our ability to truly understand the disease and move the needle, clinically and commercially.

To change the paradigm of clinical development in NASH, and ensure that risk assessments, market access and reimbursement strategies are prepared to address the unique complexities of this disease and patient population, a new approach is needed.

The status quo must change.

Harnessing the IQVIA CORE™, IQVIA helps accelerate the identification and treatment of undiagnosed patients, and offers new, evidence-based solutions in advancing results in NASH.

Challenge the status quo in NASH

Flexible solutions for Emerging Biopharma Companies
From defining the plan for your asset, to trial implementation, through launch and commercialization, IQVIA can help you find your path to success.